About this trial
Sleep-disordered breathing (SDB) describes a group of disorders in which partial or complete cessation of breathing occurs many times throughout the night, resulting in daytime sleepiness or fatigue that interferes with a person's ability to function and reduces quality of life. Transplantation has become an important treatment modality for end-stage organ failure. Transplant recipients are now living longer and, hence, develop chronic adverse medical conditions. Furthermore, transplantation is associated with weight gain. Despite the high prevalence of poor sleep and cardiovascular conditions among transplant patients, SDB is not well studied in these patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients 1 year after lung transplantation
Disqualifiers
Refusal of PSG
Medical contra-indication to perform PSG
Trial population
Patients 1 year after lung transplantation are systematically evaluated by polysomnography.
Trial design
Cohort
Prospective
Treatments tested in this trial
No intervention - Diagnostic polysomnography at 1 year after lung transplantation
Other intervention
Treatment groups
Trial outcomes
Primary outcomes
Number of participants with SDB and type (central or obstructive) of SDB
Prevalence of different types of SDB after lung transplantation
Secondary outcomes
Echocardiography
Correlations between SDB and heart function
Lung function measurement
Correlations between SDB and lung function
Blood analysis
Correlations between SDB and renal function
24h blood pressure
Evaluation of relationship between hypertension and SDB
Sponsors and contacts
Click on the lead sponsor to view all of their trials.